港股異動 | 赤子城科技(9911.HK)大漲近10% 去年營收大幅增長超200%
格隆匯4月1日丨赤子城科技(9911.HK)盤中股價拉昇走高,現漲幅為9.8%,報4.93港元,成交額超3800萬港元,總市值超49億港元。

赤子城科技3月24日發佈2020年度業績公吿,公司2020年總營收達11.8億元人民幣,同比大幅增長203.2%;年內淨利潤達1.1億元,同比增長67.1%;經調整淨利潤達1.5億元,同比增長41.5%。其中應用內購收入達到6.6億元,實現同比5549.8%的飛躍性增長。應用內購收入也成為公司主要收入來源,在總收入中的佔比達到55.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.